Title: Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.
Authors: Wan, Chao-Ling; Liu, Yu-Qing; Liu, Fang-Tong; Huang, Yuan-Hong; Cao, Han-Yu; Huang, Si-Man; Tan, Kai-Wen; Ge, Shuai-Shuai; Wang, Miao; Liu, Mei-Jing; Wang, Zi-Hao; Li, Zheng; Xue, Sheng-Li; Dai, Hai-Ping
Abstract: The article focuses on comparing the efficacy of venetoclax plus hypomethylating agents (VEN HMA) versus intensive chemotherapy in treating acute myeloid leukemia with myelodysplasia-related gene mutations (AML-MR). Topics include the impact of genetic mutations on treatment decisions, the outcomes of VEN HMA compared to standard chemotherapy, and the effects of different treatment regimens on overall and event-free survival rates in AML-MR patients.
Subjects: ACUTE myeloid leukemia; FEBRILE neutropenia; HYPOPHARYNGEAL cancer; VENETOCLAX
Publication: Blood Cancer Journal, 2024, Vol 14, Issue 1, p1
ISSN: 2044-5385
Publication type: Academic Journal
DOI: 10.1038/s41408-024-01130-7

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.

Wan, Chao-Ling; Liu, Yu-Qing; Liu, Fang-Tong; Huang, Yuan-Hong; Cao, Han-Yu; Huang, Si-Man; Tan, Kai-Wen; Ge, Shuai-Shuai; Wang, Miao; Liu, Mei-Jing; Wang, Zi-Hao; Li, Zheng; Xue, Sheng-Li; Dai, Hai-Ping